Companies Reporting Before The Bell
• CASI Pharmaceuticals (NASDAQ:CASI) is estimated to report quarterly loss at $0.06 per share on revenue of $5.05 million.
Canadian licensed cannabis producers have been faced with challenges imposed by ongoing price deflation, COVID-19 lockdowns and uncertainty over whether and when U.S. federal legalization will occur.
As a result, some Canadian cannabis companies have become dependent on value flower, according to a Cantor Fitzgerald analyst.